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Introduction
Diabetic nephropathy (DN) is the most common cause of 
end-stage renal disease (ESRD) worldwide.1 The stages of 
DN are glomerular hypertrophy, microalbuminuria, overt 
albuminuria, and finally a gradual decrease of glomerular 
filtration rate (GFR). DN occurs in 20% to 30% of diabetic 
patients, with the same frequency in diabetes type 1 and 
2.2–4 Proteinuria is a known risk factor of the progression of 
renal and cardiac diseases, and decreasing the rate of 
proteinuria may also slow the rate of GFR decline.5–11 
Angiotensin-converting enzyme inhibitors (ACEi) and 
angiotensin receptor blockers (ARBs) are the main treat-
ment for patients with diabetic nephropathy; however, 
some other therapies, such as allopurinol, have been used to 
prevent or reduce proteinuria in diabetic patients.12 To pre-
vent or treat DN, lowering blood pressure to less than 
130/80 mmHg has been recommended, especially in 
patients with proteinuria of more than 1000 mg/day. 
Continuation of treatment with ACEi may lead to increased 
serum renin to the same level as before treatment by a 
mechanism called the escape phenomenon.13–18 Diuretics 
such as hydrochlorothiazide and furosemide can activate 
RAAS by decreasing the blood volume, thereby leading to 
decreasing the efficacy of RAAS blocking agents. 
Spironolactone (a potassium-sparing diuretic) is an inhibi-
tor of spironolactone receptors in collecting tubules with a 
weak diuretic effect, therefore it has been combined with 
other diuretics to increase efficacy. It is primarily used for 
treatment of heart failure, secondary hyperaldosteronism 
(cirrhosis), and primary hyperaldosteronism (Conn’s syn-
drome).19 In some studies, it is applied in diabetic patients 
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to decrease albuminuria; however, due to its common side 
effect (hyperkalemia), its usage is limited.20–24 On the other 
hand, thiazide diuretics can cause hypokalemia and hyper-
glycemia and may also disturb control of diabetes.25 
Combining a thiazide diuretic and spironolactone for treat-
ment of DN might be effective with a lower frequency of 
hyperkalemia. This combination was used in a few studies 
with different results; therefore, the aim of our study was to 
evaluate the efficacy of combining spironolactone and 
hydrochlorothiazide versus monotherapy with these drugs.
Materials and methods
In a randomized clinical trial in the Specialized Emam Ali 
clinic in Shahrekord, 60 type 2 diabetic (T2DM) patients in 
three groups were enrolled. Twenty patients randomly 
entered each group. Inclusion criteria were: age greater 
than 40, proteinuria ≥ 150 mg/day, GFR ≥ 30 mlit/min 
(Cockgroft-Gault (CG) formula), and K < 5 meq/lit. 
Exclusion criteria were: non-cooperation during the study, 
New York Heart Association (NYHA) class 3 and 4 heart 
failure, history of hypothyroidism, change of dose of ARBs 
or ACEi during the study, serum K ≥ 5.5 during the study, 
use of pentoxifylline, and any significant or acute compli-
cation of drugs.
In patients in the first group, spironolactone 50 mg/day 
plus placebo, in the second group spironolactone 50 mg/day 
plus hydrochlorothiazide (HCTZ) 25 mg/day, and in the 
third group HCTZ 25 mg/day plus placebo were prescribed 
for three months. Before and after the study, fasting blood 
sugar (FBS), two-hour post-prandial blood sugar (2HPPBS), 
24-hour urine protein, serum K, blood urea nitrogen (BUN), 
and creatinine (Cr) were checked. These laboratory tests 
were conducted by Biotechnica Instruments (BT 3000) and 
Flame Photometer (Corning 480) Nyocard Reader II. The 
patients were taking insulin or oral hypoglycemic agents on 
an individual basis. All patients used renoprotective drugs 
(ACEi or ARB) and dosage of these drugs was not changed 
during the study. The patients were seen one week after the 
beginning of the study and then monthly for control of 
blood pressure (BP) and check of serum K (see Figure 1). 
Study data were collected with a questionnaire, entered 
using SPSS software and then evaluated by Chi square test, 
Kruskal–Wallis test, paired-samples t test, and Wilcoxon 
Signed Rank test. This study was approved by the ethics 
committee of Shahrekord University of Medical Sciences, 
Iran.
Results
The mean age of the patients was 56.8±8.3 (41–81) years. 
Twenty-six (43.3%) of the patients were male. There was 
no difference between the three groups of patients based 
on age, gender, body mass indexes (BMI), systolic and 
diastolic BP, and duration of diabetes mellitus at the 
beginning of the study, but diastolic BP decreased signifi-
cantly in the second and third group at the end of the study 
(Table 1). There was no significant difference between 
patients based on the dose of ACEi and ARBs. In the third 
group (hydrochlorothiazide + placebo), FBS increased 
significantly compared to the baseline. There was no sig-
nificant difference between groups based on the 2HPPBS, 
5 PM blood sugar (5PMBS), and hemoglobin A1C (Hb 
A1c) (Table 2). Lipid profile (total cholesterol, high- 
density lipoprotein (HDL) and low-density lipoprotein 
(LDL) cholesterol, triglycerides) in the three groups was 
the same (p > 0.05). Serum Cr increased 0.1 mg/dl and 
GFR decreased 6 mlit/min in the second group (spironol-
actone + placebo) at the end of the study (p < 0.05). Serum 
uric acid in the three patient groups did not increase sig-
nificantly. Corrected serum calcium increased 0.11 mg/dl 
in the third group (p < 0.05) and 0.06 mg/dl in the second 
group (p > 0.05). Serum phosphorus decreased signifi-
cantly in the second and third groups, as did 24-hour urine 
protein (Table 3 and Figure 2). Serum potassium increased 
significantly in the first group but it did not change in the 
Figure 1. Serum K+ of patients during study.
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two other groups (Table 4). The highest level of K in 
patients was 5.1 meq/lit.
Discussion
This study was performed on 60 T2DM patients, and the 
results showed that the combination of spironolactone and 
hydrochlorothiazide could decrease proteinuria without 
adverse effects such as hyperkalemia. GFR was decreased 
in the spironolactone group but not in the other two groups. 
In other studies similar results were reported; for example, 
Schjoedt et al.23 and Saklayen et al.26 showed that spirono-
lactone could decrease GFR, and in a study by van den 
Meiracker et al.,24 spironolactone caused a transient 
decrease of GFR. Similarly, Bianchi et al.21 showed that the 
reduction of GFR due to spironolactone is transient, and 
after one year of constant use GFR was higher than in the 
placebo group. Nevertheless, in studies by Chrysostomou 
et al.27 and Mehdi et al.,28 spironolactone did not decrease 
GFR in patients. The cause of GFR loss by spironolactone 
is not fully understood, but may be due to the decline of 
serum level of aldosterone and its effect on the retention of 
salt and water in the kidney.
A not-significant increase in serum uric acid seen in 
the third group may be due to mild volume loss and 
increased reabsorption of uric acid in the proximal 
tubule. The increased serum Ca and decreased serum 
phosphate was due to the effect of hydrochlorothiazide 
on renal tubules that was significant only in the third 
group. Proteinuria was decreased significantly in the 
first and second groups, possibly because of the effect of 
spironolactone.
A few studies have been conducted about the antipro-
teinuric effect of spironolactone in diabetic patients; for 
example, in the study by Chrysostomou and Becker,29 in 
which a prescription combination of ACEi, ARBs, and 
spironolactone versus ACEi and ARBs in combination 
reduced proteinuria in diabetic patients significantly. 
Table 1. Demographic characteristics of patients before and after study.
Spironolactone+ 
placebo
Spironolactone+ 
hydrochlorothiazide
Hydrochlorothiazide+ 
placebo
p
Age (year) 56.2±6.3 58.9±9.3 55.4±8.9 0.389
Duration of DM (kg) 9.3±5.6 9.9±4.2 8.5±4.9 0.404
BMI (kg/m2) Before study 30.2±4.4 30.3±4.4 29.3±3.3 0.672
After study 30.3±4.3 30.3±4.3 29.3±3.3 0.635
p 0.726 0.233 0.947 _
Systolic BP (mm Hg) Before study 132.8±12.8 133.5±14.5 133.5±13.2 0.993
After study 133.5±11.6 132.5±12.6 133.0±11.5 0.976
p 0.477 0.206 0.480 —
Diastolic BP (mm Hg) Before study 84.3±5.4 84±9.4 84.0±7.4 0.982
After study 83±5.9 81.5±8.6 80.0±7.1 0.477
p 0.248 0.008 0.001 —
DM: diabetes mellitus; BMI: body mass index; BP: blood pressure.
Table 2. Glycemic characteristics of patients before and after study.
Spironolactone+ 
placebo
Spironolactone+ 
hydrochlorothiazide
Hydrochlorothiazide+ 
placebo
p
FBS (mg/dl) Before study 147.2±52.5 149.9±44.2 139.7±30.1 0.888
After study 151.4±48.9 155.6±41.3 149.3±40.1 0.388
p 0.350 0.478 0.029 _
2-H PPBS (mg/dl) Before study 213.5±81.3 220±73.5 211.9±71.5 0.890
After study 213.7±82.5 203.2±63.4 213.1±64.1 0.970
p 0.779 0.135 0.709 _
BS5PM (mg/dl) Before study 176.6±69.5 209.3±74.2 178.5±50.2 0.163
After study 170.4±69.3 194.6±53.6 178.9±45.9 0.219
p 0.135 0.737 0.896 _
Hb A1c (%) Before study 7.23±0.98 7.55±1.18 7.38±0.99 0.652
After study 6.97±1.14 7.71±0.97 7.44±1.07 0.159
p 0.084 0.322 0.428 _
FBS: fasting blood sugar; 2-H PPBS: postprandial blood sugar; BS5PM: blood sugar 5 p.m.; Hb A1c: hemoglobin A1C.
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In another study on chronic kidney disease in patients 
with proteinuria who had been under treatment with reno-
protective drugs (ARBs or ACEi), Bianchi et al.21 added 
spironolactone 25 mg/day for eight weeks and concluded 
that in these patients proteinuria decreased approximately 
1000 mg/day versus the control group, and after discon-
tinuation of spironolactone proteinuria returned to basal 
level. In a similar study by Tylicki et al.30 of 18 proteinu-
ric patients, spironolactone reduced proteinuria approxi-
mately 700 mg/day compared with the control group. Also 
in a study by Navaneethan et al.,31 patients who were 
treated with spironolactone had less proteinuria compared 
with other patients. In addition, in Rossing et al.’s study,22 
spironolactone caused a 33% decline in proteinuria and 6 
mm Hg in systolic BP compared to a placebo group, and 
similar results were also obtained in a study by Schjoedt 
et al.23 Reduction of albumin to creatinine ratio in patients 
who received spironolactone was greater compared to 
patients with sisapril in a study by Rachmani et al.32 
Furthermore, aldosterone escape occurs in some patients 
under treatment with RAAS blocker drugs. In Sato 
et al.’s20 study, aldosterone escape and its effect on pro-
teinuria was evaluated; after prescription of ACEi for 40 
weeks and in 18 patients, if there was any favorable 
response to treatment, spironolactone 25 mg/day was 
given and proteinuria decreased significantly. Mehdi 
et al.28 in their study showed that spironolactone can 
reduce proteinuria in diabetic patients under treatment 
with ACEi. Saklayen et al.26 and van den Meiracker and 
colleagues24 also demonstrated that spironolactone was 
effective in reducing proteinuria. As in the patients on 
treatment with ACEi or ARBs, serum level of renin and 
plasma renin activity would increase; we could not check 
these characteristics in our study. In the patients who 
received these agents, the serum level of aldosterone 
decreased significantly because of a substantial decline in 
the amount or effect of angiotensin 2 on its receptors, so 
the effect of spironolactone on decreasing proteinuria 
might be due to other mechanisms such as an antifibrotic 
effect.33 In our study serum K+ increased significantly 
Figure 2. Twenty-four-hour protein of patients during study.
Table 3. Renal function test indices in patients before and after study.
Spironolactone+ 
placebo
Spironolactone+ 
hydrochlorothiazide
Hydrochlorothiazide+ 
placebo
p
BUN (mg/dl) Before study 16.3±4 17±5.7 17.5±4 0.619
After study 16.2±4 18.7±9 17.6±2.6 0.213
p 0.811 0.292 0.249 —
Cr (mg/dl) Before study 1.01±0.21 0.96±0.29 0.96±0.15 0.467
After study 1.1±0.27 0.96±0.27 0.95±0.16 0.028
p  
GFR (mg/dl) Before study 90.7±24.6 86.2±25 87.38±22 0.824
After study 85.1±28 85.5±23.9 88.9±25.5 0.873
p 0.043 0.762 0.388 —
24-Hour urine 
protein (mg)
Before study 377.3±250.4 432.2±210 356.2±210.1 0.324
After study 168.2±167.3 224.6±172 359.4±212.2 <0.001
p <0.001 <0.001 0.322 —
BUN: blood urea nitrogen; GFR: glomerular filtration rate.
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in the first group but not in the two other groups; never-
theless, except hyperkalemia (K+=5.7 meq/lit) in one 
patient in the third group, maximum K+ in all patients was 
not increased more than 5.1 meq/lit. Serum K+ was not 
different in the spironolactone versus control groups in 
Saklayen et al.’s study;26 however, in the study by Bianchi 
et al.,21 serum K+ was 0.8 meq/lit greater than in the pla-
cebo group. Also in a meta-analysis by Jennings et al.,34 a 
similar result was obtained.
Some thiazide diuretic side effects are hyperlipidemia, 
hyperuricemia, hypokalemia, and hyperglycemia. Glucose 
intolerance is probably due to the inhibitory effect of 
hypokalemia on insulin secretion and is less common with 
serum K+ greater than 4 meq/lit.35 Thiazide-induced 
hypokalemia, hyperglycemia, and hyperuricemia are dose 
dependent, and daily doses of 12.5 to 25 mg hydrochloro-
thiazide produce fewer side effects than doses of ≥ 50 
mg.35–37 We prescribed a low dose (25 mg/day) of HCTZ, 
and hypokalemia or hyperuricemia did not occur in the 
patients who received HCTZ plus spironolactone.
Conclusion
Spironolactone plus hydrochlorothiazide is an effective 
modality for treatment of DN especially in combination 
with ACEi or ARBs. Hyperkalemia as a common adverse 
effect of potassium-sparing diuretics was not seen with this 
combination; therefore, we suggest using these drugs for 
DN, especially in refractory cases.
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